BrainChip (BRN) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
1 Dec, 2025Executive summary
Ended the quarter with a cash balance of $13.9M, up from $13.5M in the prior quarter.
Advanced AKD1500 neuromorphic processor from reference design to volume production, driven by strong customer engagement in defense, aerospace, medical, and consumer wearables.
Expanded global IP portfolio to 57 issued and pending patents, reinforcing competitive positioning in edge AI.
Entered strategic supply agreement with Parsons Corporation for AKD1500 integration into defense platforms.
Broadened distribution through DigiKey, making Akida-based development boards globally accessible.
Financial highlights
Net operating cash outflows of $4.9M, higher than $2.8M in the prior quarter.
Customer cash inflows of $0.3M, down from $1.4M in the previous quarter due to lower engineering revenues.
Payments to suppliers and employees totaled $5.2M, up from $4.4M, reflecting merit increases, higher contractor fees, and corporate costs.
Cash inflows from financing activities of $5.4M from a capital call, with an average subscription price of A$0.2059 per share.
Estimated 2.96 quarters of funding available based on current cash burn and available facilities.
Outlook and guidance
Volume production of AKD1500 expected to drive scalable revenue growth, supported by strategic agreements and expanded distribution.
Enhanced full-stack AI capabilities position the company as a comprehensive AI solutions provider.
Latest events from BrainChip
- Revenue up 374%, net loss reduced, and $37M raised to accelerate neuromorphic AI growth.BRN
H2 202526 Feb 2026 - Revenue up 72% and net loss reduced, with strong capital raises and key commercial wins.BRN
H2 202420 Feb 2026 - Cash position strengthened and new partnerships drive momentum for neuromorphic AI products.BRN
Q4 202529 Jan 2026 - A pivotal year with a new product roadmap, higher bookings targets, and focus on shareholder alignment.BRN
AGM 202520 Nov 2025 - $35M placement and $2M SPP to accelerate edge AI commercialization and product expansion.BRN
Investor Presentation10 Nov 2025 - Edge AI and neuromorphic solutions drive growth across defense, healthcare, and consumer markets.BRN
Investor Presentation19 Oct 2025 - Revenue soared 859% and net loss narrowed, with new funding and partnerships fueling growth.BRN
H1 202521 Aug 2025 - Customer receipts surged and cash burn improved, supporting ongoing growth and innovation.BRN
Q2 202529 Jul 2025 - Cash position strengthened to US$25.6M, supporting commercialization and product development.BRN
Q3 202413 Jun 2025